Under the terms of the agreement, Beximco Pharma will receive the exclusive rights to launch Mylan’s portfolio of key monoclonal antibodies to treat different types of cancers, rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other medical conditions, a press statement said yesterday. The first product to be launched in first quarter of 2020 will be Ogivri, a breast cancer drug which is biosimilar to blockbuster drug Herceptin from Roche with global sales in excess of $7 billion in 2018. This commercial agreement with Beximco Pharmaceuticals, will help patients of Bangladesh to access Trastuzumab.
Ogivri is approved the US Food and Drug Administration and also has received marketing authorisation from the European Medicines Agency.
Cancer is now one of the leading causes of death in Bangladesh and currently there are more than 50,000 HER2-positive breast cancer patients in the country.
Beximco Pharma is a leading exporter of pharmaceuticals in Bangladesh. The company currently has a global footprint in more than 50 countries and has been accredited by the leading global regulatory authorities including US FDA, Malta Medicines Authority (EU), TGA (Australia), Health Canada, GCC (Gulf) and TFDA (Taiwan).